Glycoprotein IIb-IIIa inhibitors in unstable coronary syndromes and percutaneous interventions--a conservative approach.
Antagonists of platelet glycoprotein IIb/IIIa have an approved role in preventing acute complications and coronary events in the setting of percutaneous coronary interventions (PCI). Their use in unstable coronary syndromes out of the PCI setting is however debated. This paper summarizes reasons for the ongoing debate and highlights areas of uncertainty.